Gao M, Georgiou A, Lin VS, Jahja M, White CA, Anderson MA, McCormack MP, Roberts AW, Huang DCS, Thijssen R. Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications. British Journal of Haematology. 2024;:10.1111/bjh.19604
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42(5):10.1016/j.ccell.2024.04.004
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson S-J, Seymour JF, Roberts AW, Tam CS. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024;:10.1182/blood.2023023388
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Advances. 2024;8(8):10.1182/bloodadvances.2023011741
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood Advances. 2024;8(6):10.1182/bloodadvances.2023011327
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?. Blood Cancer Journal. 2024;14(1):10.1038/s41408-024-00996-x
Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D’Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ, Wei AH, Group ALAL. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood. 2023;142(23):10.1182/blood.2023020301
Gopalakrishnan S, Menon R, Suleiman AA, Kater AP, Stilgenbauer S, Seymour JF, Chyla B, Lu T, Kim SY, Roberts AW, Woyach JA, Mensing S, Salem AH. Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies. HemaSphere. 2023;7(12):10.1097/hs9.0000000000000983
Chua CC, Anstee N, Flensburg C, Teh C, Ivey A, Amin N, Thijssen R, Bohlander SK, Kakadia PM, Xu Z, Fong CY, Ting S, Loo S, Tiong IS, Gray D, Fleming S, Davidson N, Roberts AW, Majewski I, Wei AH, Brown FC. Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations. Blood. 2023;142(Supplement 1):10.1182/blood-2023-185321
Yuan Y, Diepstraten ST, Brown FC, Litalien V, Strasser A, Kelly GL, Roberts AW, Wei AH. Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo. Blood. 2023;142(Supplement 1):10.1182/blood-2023-179698
